Drug Profile
BVA 701
Alternative Names: BVA-701Latest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator Biovista
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Glioblastoma; Malignant melanoma; Thyroid cancer
Highest Development Phases
- Preclinical Glioblastoma; Malignant melanoma; Thyroid cancer
Most Recent Events
- 25 Aug 2022 Preclinical development is ongoing in USA (Biovista pipeline, August 2022)
- 12 Jul 2016 BVA 701 is available for licensing as of 12 Jul 2016. http://www.biovista.com/
- 12 Jul 2016 Preclinical trials in Glioblastoma in USA (unspecified route)